Research Library
Retatrutide Identity and Quality: Connecting the Material to the Evidence
Retatrutide’s clinical research is tied to a precisely defined molecule. Connecting any tested material to that evidence requires more than matching the name—it requires credible identity, content,...
Read focused articleMRI-Measured Liver Fat in the LY3437943 Phase 2 Substudy
Investigators reported striking liver-fat changes in a randomized LY3437943 substudy—one of the most closely watched findings outside the primary body-weight and glycemic endpoints. The study offer...
Read focused articleUnderstanding Retatrutide, Tirzepatide, and Semaglutide Trial Comparisons
Retatrutide, tirzepatide, and semaglutide represent three stages in the development of incretin-based metabolic research: single-, dual-, and triple-receptor strategies. Comparing them is scientifi...
Read focused articleRetatrutide Safety: What the Evidence Currently Shows
Retatrutide’s clinical program has already produced a recognizable tolerability profile. Understanding what researchers observed—and what longer follow-up still needs to establish—is essential to e...
Read focused articleRetatrutide Phase 3: What the TRIUMPH Program Has Actually Shown
TRIUMPH is an unusually broad Phase 3 program spanning general obesity, type 2 diabetes, cardiovascular disease, osteoarthritis, sleep apnea, head-to-head comparison, treatment escalation, longer-t...
Read focused articleWhat Is Retatrutide? Why the Triple-Agonist Design Matters
Lilly’s LY3437943 represents one of the most ambitious ideas in modern metabolic-peptide research: combining GIP, GLP-1, and glucagon-receptor activity within one investigated molecule. The program...
Read focused articleWhat the LY3437943 DXA Substudy Reported About Body Composition
The LY3437943 body-composition substudy drew interest because large body-weight changes were accompanied by substantial changes in measured fat mass. The next research question is how lean tissue, ...
Read focused articleBody-Weight Findings in Retatrutide Trials
Trials of Lilly’s investigated LY3437943 have reported some of the largest mean body-weight changes in randomized metabolic research. These results are a major reason for scientific interest in the...
Read focused article